Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Objective: Persons with schizophrenia and other psychotic disorders frequently have coexisting substance use disorders that require modifications to treatment approaches for best outcomes. The objectives of this review were to identify evidence-based practices best practices that improve outcomes for individuals with schizophrenia and substance used disorders. Method: We reviewed guidelines that were published in the last 5 years and that included systematic reviews or meta-analyses. Most of our recommendations came from 2 publications from the National Institute for Health and Care Excellence (NICE): the 2011 guidance titled Coexisting Severe Mental Illness (Psychosis) and Substance Misuse: Assessment and Management in Healthcare Settings and the 2014 guidance titled Psychosis and Schizophrenia in Adults: Prevention and Management. We placed these recommendations into the Canadian context to create this guideline. Results: Evidence supports the inclusion of individuals with coexisting substance use disorders in first-episode psychosis programs. The programs should integrate psychosis and substance use treatments, emphasizing ongoing monitoring of both substance use and patterns and symptoms. The best outcomes are achieved with combined use of antipsychotic medications and addiction-based psychosocial interventions. However, limited evidence is available to recommend using one antipsychotic medication over another or one psychosocial intervention over another for persons with schizophrenia and other psychotic disorders with coexisting substance use disorders. Conclusions: Treating persons who have schizophrenia and other psychotic disorders with coexisting substance use disorders can present clinical challenges, but modifications in practice can help engage and retain people in treatment, where significant improvements over time can be expected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Kessler, R. C., Nelson, C. B., McGonagle, K. A., Edlund, M. J., Frank, R. G., & Leaf, P. J. (1996) · American Journal of Orthopsychiatry · doi:10.1037/h0080151 · Cited by 1,378
de Leon, J., & Diaz, F. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.010 · Cited by 1,276 · cited 1×
“In addition, cigarette smoking has been reported in 60% to 90% of persons with schizophrenia and other psychotic disorders.(3,4) Cannabis and stimulant use, in particular, appear to be associated with the development of psychotic symptoms; cannabis use appears to be an independent risk factor for the development of pe…”
BackgroundJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Family intervention for schizophrenia
Pharoah, F., Mari, J., Rathbone, J., & Wong, W. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000088.pub2 · Cited by 737
Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study
Crump, C., Winkleby, M. A., Sundquist, K., & Sundquist, J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050599 · Cited by 619
Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes
DIXON, L. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00161-3 · Cited by 472
Drake, R. E., O'Neal, E. L., & Wallach, M. A. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.01.011 · Cited by 447 · cited 2×
“When treating patients with psychosis and coexisting substance use disorders, the focus should be on retention in treatment, gradual change in substance use behaviour over time (decreased use initially aiming for abstinence), improved physical and mental health and improved function as the primary treatment targets.(3…”
BackgroundCannabis as a risk factor for psychosis: Systematic review
Semple, D. M., McIntosh, A. M., & Lawrie, S. M. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105049040 · Cited by 420
Interventions for smoking cessation and reduction in individuals with schizophrenia
Tsoi, D. T., Porwal, M., & Webster, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007253.pub3 · Cited by 304
Bobes, J., Arango, C., Garcia-Garcia, M., & Rejas, J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1030 · Cited by 181 · cited 3×
“The process was facilitated through the Canadian Journal of Psychiatry and the Schizophrenia Society of Canada.”
BackgroundThe impact of substance use disorders on the course of schizophrenia—A 15-year follow-up study
Schmidt, L. M., Hesse, M., & Lykke, J. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.011 · Cited by 171
Williams, J. M., Anthenelli, R. M., Morris, C. D., Treadow, J., Thompson, J. R., Yunis, C., & George, T. P. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07522 · Cited by 162
Treatment of Dual Diagnosis Disorders
Murthy, P., & Chand, P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328351a3e0 · Cited by 115
Couple and family involvement in adult mental health treatment: a systematic review
Meis, L. A., Griffin, J. M., Greer, N., Jensen, A. C., MacDonald, R., Carlyle, M., Rutks, I., & Wilt, T. J. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2012.12.003 · Cited by 92
Wisdom, J. P., Manuel, J. I., & Drake, R. E. (2011) · Psychiatric Services · doi:10.1176/appi.ps.62.9.1007 · Cited by 53 · cited 1×
“Interestingly, for early psychosis populations, to date the evidence suggests that additional treatments beyond those involving assessment and monitoring of substance use on top of typical services provided in an early psychosis program have not been shown to be more effective.(32) It may be that the ability to demons…”
BackgroundEight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia
Morden, N. E., Lai, Z., Goodrich, D. E., MacKenzie, T., McCarthy, J. F., Austin, K., Welsh, D. E., Bartels, S., & Kilbourne, A. M. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.02.009 · Cited by 44
Cited by
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
Psychosocial interventions for people with both severe mental illness and substance misuse
Hunt, G. E., Siegfried, N., Morley, K., Brooke-Sumner, C., & Cleary, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001088.pub4 · Cited by 105
Concurrent Disorder Management Guidelines. Systematic Review
Hakobyan, S., Vazirian, S., Lee-Cheong, S., Krausz, M., Honer, W. G., & Schutz, C. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082406 · Cited by 99
“9 Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders [36] CPA Canada 2017 People with schizophrenia and other psychotic disorders with coexisting substance use disorders”
BackgroundRafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221142575 · Cited by 41
“More recently, the Canadian (Crockford and Addington, 2017) and Spanish (Arranz et al., 2022) guidelines for schizophrenia did not recommend using one antipsychotic over another for individuals with comorbid SUDs due to limited evidence from randomized prospective trials.”
BackgroundBogers, J. P. A. M., Hambarian, G., Michiels, M., Vermeulen, J., & de Haan, L. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa002 · Cited by 33
Metadata
- Authors
- Crockford, D., & Addington, D.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2017-09
- Volume
- 62
- Issue
- 9
- Pages
- 624-634
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W2751095973
- Cited by
- 113
- References
- 21
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.